Skip to main content
Log in

Therapy

Low-dose flutamide for hirsutism: into the limelight, at last

  • News & Views
  • Published:

From Nature Reviews Endocrinology

View current issue Sign up to alerts

Evidence indicates that flutamide, a specific and potent androgen-receptor blocker, when given in low dose (∼1 mg/kg daily), confers a first-choice balance between antiandrogenic efficacy and hepatic safety for women and adolescent girls with hirsutism or other androgen-related symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Paradisi, R. & Venturoli, S. Retrospective observational study on the effects and tolerability of flutamide in a large population of patients with various kinds of hirsutism over a 15-year period. Eur. J. Endocrinol. doi:10.1530/eje-10-0100.

  2. Wysowski, D. K. & Fourcroy, J. L. Flutamide hepatotoxicity. J. Urol. 155, 209–212 (1996).

    Article  CAS  Google Scholar 

  3. Martin, K. A. et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 1105–1120 (2008).

    Article  CAS  Google Scholar 

  4. Muderris, I. I., Bayram, F. & Guven, M. Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day). Gynecol. Endocrinol. 14, 38–41 (2000).

    Article  CAS  Google Scholar 

  5. Ibáñez, L. & de Zegher, F. Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. J. Clin. Endocrinol. Metab. 88, 4720–4724 (2003).

    Article  Google Scholar 

  6. Calaf, J. et al. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism. A 12-month, double-blind, parallel clinical trial. J. Clin. Endocrinol. Metab. 92, 3446–3452 (2007).

    Article  CAS  Google Scholar 

  7. Ibáñez, L., Valls, C., Cabré, S. & de Zegher, F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. J. Clin. Endocrinol. Metab. 89, 4716–4720 (2004).

    Article  Google Scholar 

  8. Ibáñez, L. & de Zegher, F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum. Reprod. Update 12, 243–252 (2006).

    Article  Google Scholar 

  9. Ibáñez, L. et al. Low-dose pioglitazone and low-dose flutamide added to metformin and estro-progestagens for hyperinsulinemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months. Clin. Endocrinol. 71, 351–357 (2009).

    Article  Google Scholar 

  10. de Zegher, F. & Ibáñez, L. Flutamide for androgen excess: low dose is best. J. Pediatr. Adolesc. Gynecol. doi:10.1016/j.jpag.2010.02.005.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lourdes Ibáñez.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Zegher, F., Ibáñez, L. Low-dose flutamide for hirsutism: into the limelight, at last. Nat Rev Endocrinol 6, 421–422 (2010). https://doi.org/10.1038/nrendo.2010.119

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2010.119

  • Springer Nature Limited

This article is cited by

Navigation